Zobrazeno 1 - 10
of 36
pro vyhledávání: '"María Gion"'
Autor:
Antonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, Pablo Tolosa, Salvador Blanch, Adela Fernández-Ortega, Ander Urruticoechea, Isabel Blancas, Cristina Saura, Beatriz Rojas, Begoña Bermejo, José Ponce Lorenzo, María Gion, Patricia Cortez-Castedo, Elisenda Llabres, Elena Galve, Juan Fernando Cueva, Ana López, José Luis Alonso-Romero, Santiago González-Santiago, Eduardo Martínez de Dueñas, Eva Ciruelos, Griselda Martrat, Petra Gener, Daniel Alcalá-López, Miguel Sampayo-Cordero, Fernando Gómez-Peralta, Javier Cortés
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102520- (2024)
Summary: Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2−/PIK3CA-mutated advan
Externí odkaz:
https://doaj.org/article/c5ba8bd9a6864624b463e00529accd71
Autor:
Emma Franco-Mateos, Virginia Souza-Egipsy, Laura García-Estévez, José Pérez-García, María Gion, Laia Garrigós, Patricia Cortez, Cristina Saavedra, Patricia Gómez, Carolina Ortiz, Víctor L. Cruz, Javier Ramos, Javier Cortés, Juan F. Vega
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3940 (2024)
The binding activity of various trastuzumab biosimilars versus the branded trastuzumab towards the glycosylated extracellular domain of the human epidermal growth factor receptor 2 (HER2) target in the presence of pertuzumab was investigated. We empl
Externí odkaz:
https://doaj.org/article/7a553e0d4e774cfbbda4c211cf4c834c
Autor:
Miguel Sampayo-Cordero, Bernat Miguel-Huguet, Andrea Malfettone, Elena López-Miranda, María Gion, Elena Abad, Daniel Alcalá-López, Jhudit Pérez-Escuredo, José Manuel Pérez-García, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
De-escalation trials in oncology evaluate therapies that aim to improve the quality of life of patients with low-risk cancer by avoiding overtreatment. Non-inferiority randomized trials are commonly used to investigate de-intensified regimens with si
Externí odkaz:
https://doaj.org/article/4129d5abe3b54a4aa1163a0967a18f28
Autor:
Matilde Sánchez-Conde, Pilar Vizcarra, José Manuel Pérez-García, María Gion, María Pilar Martialay, Javier Taboada, Alberto Alonso-Fernández, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De La Torre, Antonio Llombart-Cussac, Javier Cortés
Publikováno v:
International Journal of Infectious Diseases, Vol 123, Iss , Pp 97-103 (2022)
Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- inter
Externí odkaz:
https://doaj.org/article/03300a66cee940b7bc9b769d46d85504
Autor:
Víctor Albarrán, Jesús Chamorro, Javier Pozas, María San Román, Diana Isabel Rosero, Cristina Saavedra, María Gion, Alfonso Cortés, Elena Escalera, Eva Guerra, Elena López Miranda, María Fernández Abad, Noelia Martínez Jañez
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and
Externí odkaz:
https://doaj.org/article/e86c0ec339974c8c8252d1bb6e51b17f
Autor:
Victor L. Cruz, Virginia Souza-Egipsy, María Gion, José Pérez-García, Javier Cortes, Javier Ramos, Juan F. Vega
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 15, p 12031 (2023)
The binding affinity of trastuzumab and pertuzumab to HER2 has been studied using both experimental and in silico methods. The experiments were conducted using the antibodies in their complete IgG form, as used in clinical therapy, and the extracellu
Externí odkaz:
https://doaj.org/article/2c67e1bc901b4313937ba74e0460c2c0
Autor:
Cristina Saavedra, Alejandro Vallejo, Federico Longo, Juan José Serrano, María Fernández, María Gion, Elena López-Miranda, Noelia Martínez-Jáñez, Eva Guerra, Jesús Chamorro, Diana Rosero, Héctor Velasco, Adrián Martín, Alfredo Carrato, José Luis Casado, Alfonso Cortés
Publikováno v:
Cancers, Vol 15, Iss 7, p 2000 (2023)
Few data are available about the immune response to mRNA SARS-CoV-2 vaccines in patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). We conducted a prospective, single-center study of patients with breast cancer tre
Externí odkaz:
https://doaj.org/article/79c0f12794274383b9fbb808ec156489
Autor:
María Gion, José Manuel Pérez-García, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Javier Cortés, Andrea Malfettone
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Drug approval for early-stage breast cancer (EBC) has been historically granted in the context of registration trials based on adequate outcomes such as disease-free survival and overall survival. Improvements in long-term outcomes have made it more
Externí odkaz:
https://doaj.org/article/8b548ce9bba54c9ca2cb0709f0aef8b1
Autor:
Luis de la Cruz-Merino, María Gion, Josefina Cruz-Jurado, Vanesa Quiroga, Raquel Andrés, Fernando Moreno, Jose L. Alonso-Romero, Manuel Ramos, Esther Holgado, Javier Cortés, Elena López-Miranda, Fernando Henao-Carrasco, Natalia Palazón-Carrión, Luz M. Rodríguez, Isaac Ceballos, Maribel Casas, Sara Benito, Massimo Chiesa, Susana Bezares, Rosalia Caballero, Carlos Jiménez-Cortegana, Víctor Sánchez-Margalet, Federico Rojo
Publikováno v:
Cancers, Vol 13, Iss 21, p 5432 (2021)
The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term clinical benefit in HER2-negative advanced breast cancer patients. Treatment consisted of 21-day cycles of 200 mg of pembrolizumab
Externí odkaz:
https://doaj.org/article/f493f8a297a3479694a4af97c2b66c7c
Publikováno v:
Cancer. 129:1791-1794